These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39102694)

  • 1. Targeted therapies in children with renal cell carcinoma (RCC): An International Society of Pediatric Oncology-Renal Tumor Study Group (SIOP-RTSG)-related retrospective descriptive study.
    Sprokkerieft J; van der Beek JN; Spreafico F; Selle B; Thebaud E; Chowdhury T; Brok J; Ottóffy G; Sun X; Ramírez Villar GL; Sagoyan G; Segers H; Doganis D; Serra A; Lemelle L; Graf N; Verschuur AC; Tytgat GAM; van den Heuvel-Eibrink MM
    Cancer Med; 2024 Jan; 13(1):e6782. PubMed ID: 39102694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001 and UK-IMPORT database: A report of the SIOP-Renal Tumor Study Group.
    van der Beek JN; Hol JA; Coulomb-l'Hermine A; Graf N; van Tinteren H; Pritchard-Jones K; Houwing ME; de Krijger RR; Vujanic GM; Dzhuma K; Schenk JP; Littooij AS; Ramírez-Villar GL; Murphy D; Ray S; Al-Saadi R; Gessler M; Godzinski J; Ruebe C; Collini P; Verschuur AC; Frisk T; Vokuhl C; Hulsbergen-van de Kaa CA; de Camargo B; Sandstedt B; Selle B; Tytgat GAM; van den Heuvel-Eibrink MM
    Int J Cancer; 2021 Jun; 148(11):2724-2735. PubMed ID: 33460450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study.
    Geller JI; Cost NG; Chi YY; Tornwall B; Cajaiba M; Perlman EJ; Kim Y; Mullen EA; Glick RD; Khanna G; Daw NC; Ehrlich P; Fernandez CV; Dome JS;
    Cancer; 2020 Dec; 126(23):5156-5164. PubMed ID: 32926409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
    Markham A
    Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
    Soleimani M; Nappi L; Kollmannsberger C
    Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and treatment of renal cell carcinoma in children: a report from the Polish pediatric rare tumor study group.
    Stachowicz-Stencel T; Bien E; Balcerska A; Godzinski J; Synakiewicz A; Perek-Polnik M; Kurylak A; Pietras W; Kuzmicz M; Mizia-Malarz A; Rybczynska A; Nurzynska-Flak J
    Klin Padiatr; 2011 May; 223(3):138-41. PubMed ID: 21509711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
    Fumarola C; La Monica S; Bonelli M; Zoppi S; Alfieri R; Galetti M; Gnetti L; Campanini N; Pozzi G; Cavazzoni A; Mazzaschi G; Silini EM; Buti S; Petronini PG
    Biochem Pharmacol; 2024 Aug; 226():116397. PubMed ID: 38944394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
    Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
    Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
    Miller K; Bergmann L; Doehn C; Gschwend J; Keilholz U
    Aktuelle Urol; 2017 Feb; 48(1):72-78. PubMed ID: 28403496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
    Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
    Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study.
    Işık D; Kınıkoğlu O; Akdağ G; Altıntaş YE; Türkoğlu E; Yildirim S; Sürmeli H; Başoğlu T; Odabaş H; Turan N
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064516
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of advanced pediatric renal cell carcinoma.
    Ambalavanan M; Geller JI
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27766. PubMed ID: 31012542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
    Spisarová M; Melichar B; Vitásková D; Študentová H
    Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
    Molina AM; Feldman DR; Ginsberg MS; Kroog G; Tickoo SK; Jia X; Georges M; Patil S; Baum MS; Reuter VE; Motzer RJ
    Invest New Drugs; 2012 Feb; 30(1):335-40. PubMed ID: 20711632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.